Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Cardiva Forsees ‘Room To Run’ For Its Unique Vascular Closure Devices

Executive Summary

Cardiva Medical is taking advantage of the growing demand for products that safely and quickly close the access sites created for catheter-based electrophysiology procedures and other large-catheter cardiac procedures. The company has a sales staff entirely dedicated to its line of closure devices for multi-site venous closure for 6-12 French inner diameter sheaths, and is investing in clinical trials to show how these devices can improve patients’ recovery time and reduce the risk of complications.

You may also be interested in...



Cardiva's Vascade System Now Approved For Vein Closures After Cardiac Surgery

Vascular Closure Market Makes Room For Innovative Solutions

The $1 billion vascular closure market is primed for growth. It comes on the back of intensive R&D that has spawned a range of alternatives to the traditional manual/compression approach, giving SJM and the sector’s other heavyweights cause to look over their shoulders.

News We’re Watching: FDA Approves Medtronic's Affera, Roche's CGM Moves Closer To Approval, And More

Medtech Insight's News We're Watching covers medtech industry and research news you may have missed. This week, the Advanced Technologies and Treatments for Diabetes (ATTD) conference in Florence, Italy, included new results from studies of Roche's continuous glucose monitor and Medtronic's 780G insulin pump, Medtronic moved closer to earning FDA approval for its Affera ablation mapping and ablation system, and Linus Health expanded its technology for finding signs of cognitive problems in speech data.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

MT124780

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel